Trial Profile
Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Malaria vaccine (Primary) ; Agatolimod; Aluminium hydroxide
- Indications Falciparum malaria
- Focus Adverse reactions; Pharmacodynamics
- 07 Feb 2017 According to NCT the study start date, primary completion date and the completion date are all given as 15 Dec 2006, so have not updated it. Study dates retained as per media release.
- 08 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.